MLN3126 structure
|
Common Name | MLN3126 | ||
---|---|---|---|---|
CAS Number | 628300-71-0 | Molecular Weight | 446.902 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C21H19ClN2O5S | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of MLN3126MLN3126 (MLN 3126, MLN-3126) is a potent, selective, orally available CCR9 antagonist with IC50 of 6.3 nM (CCL25-induced calcium mobilization); shows no significant antagonistic activity for other 12 chemokine receptors (CCR1, -2b, -4, -6, -7, -8, -10,CX3CR1, CXCR1, -2, -3 and -4) at 10 uM; dose dependently inhibits CCL25-induced chemotaxis of mouse thymocytes (IC90=1.8 uM); ameliorates inflammation in a T cell mediated mouse colitis model. Other Indication Phase 1 Discontinued |
Name | MLN3126 |
---|
Description | MLN3126 (MLN 3126, MLN-3126) is a potent, selective, orally available CCR9 antagonist with IC50 of 6.3 nM (CCL25-induced calcium mobilization); shows no significant antagonistic activity for other 12 chemokine receptors (CCR1, -2b, -4, -6, -7, -8, -10,CX3CR1, CXCR1, -2, -3 and -4) at 10 uM; dose dependently inhibits CCL25-induced chemotaxis of mouse thymocytes (IC90=1.8 uM); ameliorates inflammation in a T cell mediated mouse colitis model. Other Indication Phase 1 Discontinued |
---|---|
References | References 1. Igaki K, et al. Int Immunopharmacol. 2018 Jul;60:160-169. 2. Narita N, et al. Drug Metab Dispos. 2018 Mar;46(3):204-213. View Related Products by Target Chemokine Receptor (CCR and CXCR) Other Indication |
Molecular Formula | C21H19ClN2O5S |
---|---|
Molecular Weight | 446.902 |